Apr 13 2016
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
The data showed that AB-PA01 was capable of infecting and killing 87.8% of 369 Pseudomonas aeruginosa (P. aeruginosa) clinical isolates from a global population of cystic fibrosis (CF) patients. AB-PA01 also demonstrated activity against 83.3% of 60 P. aeruginosa global, clinical isolates from non-CF patients. In total, AB-PA01 was shown to be active in vitro against 87.2% of the 429 clinical isolates tested, including both multi-drug resistant (MDR) and sensitive strains of P. aeruginosa. Additionally, in an acute murine lung infection model all AB-PA01 doses administered demonstrated activity similar to meropenem.
M. Scott Salka, CEO of AmpliPhi Biosciences, commented:
Most CF patients suffer from chronic and MDR P. aeruginosa infections, sadly causing morbidity and mortality. The need for alternative therapies is urgent as CF patients’ bacterial populations have become increasingly resistant to broad-spectrum antibiotics. We are excited by the current data and the potential for AB-PA01 to address this great unmet need in the CF patient population.
Sandra Morales, Ph.D., AmpliPhi’s Vice President of Research, added:
These new data further highlight a compelling case for the potential of bacteriophage cocktails to treat P. aeruginosa infections in CF patients where the existence of biofilms and multi-drug resistant bacteria are increasingly problematic. Our research has been focused on developing a phage cocktail with a sufficiently broad range of activity to minimize the frequency of bacterial resistance observed in individual phage components.
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses